senolytics
70% Rise In Longevity Science Revenue From Senolytics
70% Rise In Longevity Science Revenue From Senolytics Senolytics are currently outpacing calorie restriction mimetics in revenue growth, delivering a 70% lift projected by 2028, though mimetics are closing the gap with strong clinical signals. In the race against aging, investors and scientists keep asking which class will dominate the